Moderna Gets FDA Approval for mRNA Flu Vaccine, But CDC Input Still Uncertain

Moderna received FDA approval for its mRNA flu vaccine mFLUSIVA for adults 50 and older, enabling quicker updates to match circulating strains. The vaccine still requires CDC advisory committee recommendation, which is delayed due to ongoing litigation affecting vaccine schedules.

This Wire brief sits within Fusion42's coverage of Health, and 3 sources have reported it between 6 Aug 2026 and 8 Aug 2026.